ArticleClinical rheumatology2026
Association between systemic inflammation-immune index and comorbidities in patients with ankylosing spondylitis: a cross-sectional study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThe systemic inflammation-immune index (SII) is a biomarker for various diseases; however, its relationship with comorbidities in ankylosing spondylitis (AS) remains unclear. This study aimed to investigate the relationship between SII and the comorbidities associated with AS.
methodThe cross-sectional study collected data from 688 patients treated at a grade A tertiary hospital in Jiangsu Province between 2021 and 2025. The SII was calculated based on platelet, neutrophil, and lymphocyte counts. Logistic regression analyses were performed. The nonlinear relationship between SII and comorbidities was examined using restricted cubic splines, and interactions between groups were identified through the likelihood ratio test.
resultsA total of 688 patients were included in the study: 233 with comorbidities and 455 without. The average age was 52.0 ± 14.4 years, with 68.8% being male and 31.2% being female. The incidence of comorbidities was 33.9%. After adjusting for certain covariates, a positive correlation between the SII and comorbidities (OR = 1.3, 95% CI [1.03, 1.64], P = 0.025) was observed, indicating independence from other confounding factors. A non-linear relationship was found between SII and the incidence of comorbidities, with a threshold of approximately 458. Subgroup analysis revealed a significant interaction between SII and disease duration/HLA-B27 (P for interaction < 0.05). A significant additive interaction was observed between SII and disease duration of over 10 years (RERI = 2.49, 95% CI [0.46, 4.52]; AP = 0.52, 95% CI [0.25, 0.79]; SI = 2.92, 95% CI [1.09, 7.85]; P = 0.01). A significant multiplicative interaction exists between HLA-B27( +) and high SII (OR = 2.5, P = 0.03).
conclusionsA substantial correlation exists between SII and AS comorbidities, indicating its potential as a predictive biomarker. Key Points • A substantial correlation exists between SII and AS comorbidities. • A non-linear relationship was found between SII and the incidence of comorbidities. • Subgroup analysis revealed a significant interaction between SII and disease duration/HLA-B27.
Indexed as
Identifiers
41874871What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.